


16th
ICML
Virtual Edition

**International
Conference
on Malignant
Lymphoma**
Lugano

June
18-22
2021



Program Book

Updated on June 14

Organized by




In cooperation with



American Association
for Cancer Research[®]

FINDING CURES TOGETHER[™]





16th
ICML

Virtual Edition

**International
Conference
on Malignant
Lymphoma**

Lugano

June
18-22
2021

 **ADcetris**[®]
brentuximab vedotin

BRINGING
Hope TO Life

The 16-ICML Program Book production has been supported by an unrestricted educational grant by TAKEDA ONCOLOGY

CONTENTS

- 4 OUR TEAM
- 6 ACKNOWLEDGEMENTS
- 8 GENERAL INFORMATION
- 10 SCIENTIFIC PROGRAM
- 34 POSTER PRESENTATIONS
- 36 INDUSTRY PROGRAM – SATELLITE SYMPOSIA AGENDA
- 55 INDUSTRY PROGRAM – VIRTUAL EXHIBITION AREA

OUR TEAM

INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA (ICML) and FOUNDATION FOR THE INSTITUTE OF ONCOLOGY RESEARCH (IOR) PRESIDENT
Franco Cavalli, Bellinzona (Switzerland)

ICML ORGANIZING COMMITTEE CHAIRMAN
Francesco Bertoni, Bellinzona (Switzerland)

ICML ORGANIZING COMMITTEE
(based in Bellinzona)

Michele Ghielmini
Alden Moccia
Bertrand Nadel, Marseilles (France) - Representative of American Association for Cancer Research (AACR)
Fedro Peccatori, Milan (Italy) - Representative of European School of Oncology (ESO)
Davide Robbiani
Davide Rossi
Anastasios Stathis
Georg Stüssi
Emanuele Zucca

16-ICML ADVISORY BOARD

James O. Armitage, Omaha, NE (USA) - CHAIRMAN
Helmut Beltraminelli, Locarno (Switzerland)
Elias Campo, Barcelona (Spain)
Bruce D. Cheson, Washington, D.C. (USA)
Nicholas Chiorazzi, Manhasset, NY (USA)
Wee Joo Chng, Singapore (Singapore)
Riccardo Dalla-Favera, New York, NY (USA)
Stephan Dirnhofer, Basel (Switzerland)
Martin Dreyling, Munich (Germany)
Jonathan W. Friedberg, Rochester, NY (USA)
Gianluca Gaidano, Novara (Italy)
Philippe Gaulard, Créteil (France)
Mary K. Gospodarowicz, Toronto, ON (Canada)
Peter W.M. Johnson, Southampton (UK)
Brad S. Kahl, St. Louis, MO (USA)
Ralf Küppers, Essen (Germany)
John P. Leonard, New York, NY (USA)
T. Andrew Lister, London (UK)

Markus G. Manz, Zurich (Switzerland)
Ari M. Melnick, New York, NY (USA)
Koichi Ohshima, Kurume (Japan)
Astrid Pavlovsky, Buenos Aires (Argentina)
Leticia Quintanilla-Martinez de Fend, Tübingen (Germany)
S.Vincent Rajkumar, Rochester, MN (USA)
Kerry J. Savage, Vancouver BC (Canada)
John F. Seymour, Melbourne (Australia)
Margaret A. Shipp, Boston, MA (USA)
Lena Specht, Copenhagen (Denmark)
Catherine Thieblemont, Paris (France)
Pier Luigi Zinzani, Bologna (Italy)
Wilhelm Wössmann, Hamburg (Germany)
Weili Zhao, Shanghai (China)

CONFERENCE SECRETARIAT

Cristiana Brentan, Federica Cariglia, Angela Kurtz,
Orietta Lugli, Chiara Saporiti
Foundation for the Institute of Oncology Research (IOR)
Via Vela 6, CH-6500 Bellinzona

ADCETRIS® (brentuximab vedotin) now has 5-year follow up data across frontline stage IV HL and PTCL indications.^{1,2} Visit the Takeda booth to learn more.



ADCETRIS® has demonstrated sustained efficacy, balanced with a well-characterized and generally manageable tolerability profile^{1-7*}



ONCOLOGY

*For further information for healthcare professionals, see www.swissmedicinfo.ch.

ADCETRIS® is indicated for adult patients with: previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD); CD30+ HL, after autologous stem cell transplantation (ASCT) at increased risk of relapse or progression; relapsed or refractory (r/r) CD30+ HL after ASCT or after a minimum of two previous treatments when stem cell transplantation is no treatment option; r/r systemic anaplastic large cell lymphoma (sALCL); previously untreated CD30+ peripheral T-cell lymphoma (PTCL) in combination with cyclophosphamide, doxorubicin, and prednisone (CHP); CD30+ cutaneous T-cell lymphoma (CTCL) that have progressed on systemic therapy or for whom other systemic therapy does not come into question.²

ADCETRIS®
brentuximab vedotin
BRINGING
Hope To Life

Adcetrís® (brentuximab vedotin), Anti-CD30 antibody-drug conjugate (ADC). Recombinant chimeric IgG1 antibody conjugated with the cytotoxic agent monomethyl auristatin E (MMAE). **PF:** Powder for concentrate for solution for infusion. **I:** Previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with chemotherapy with doxorubicin, vinblastine and dacarbazine (AVD). CD30+ HL at increased risk of relapse or progression after autologous stem cell transplantation (ASCT). Relapsed or refractory CD30+ HL after ASCT or after minimum two previous treatments if a stem cell transplantation is no treatment option. Previously untreated CD30+ peripheral T-cell lymphoma (PTCL) in combination with chemotherapy with cyclophosphamide, doxorubicin and prednisone (CHP). Relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). CD30+ cutaneous T-cell lymphoma (CTCL) after progression under systemic therapy or if another systemic therapy does not come into question. **D:** The recommended dose, as monotherapy or in combination with CHP, is 1.8 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks. The recommended dose in combination with AVD is 1.2 mg/kg administered as an intravenous infusion over 30 minutes on days 1 and 15 of each 28-day cycle. If the patient's weight is more than 100 kg, the dose calculation should use 100 kg. **CI:** Hypersensitivity to ingredients. Combined use with bleomycin. **W&P:** Progressive multifocal leukoencephalopathy, pancreatitis, serious infections and opportunistic infections, infusion-related reactions, pulmonary toxicity, tumor lysis syndrome, peripheral neuropathy (sensory/motor), hematological toxicity including febrile neutropenia, Stevens-Johnson syndrome and toxic epidermal necrolysis, increased toxicity in case of severe renal and moderate or severe hepatic impairment, hepatotoxicity, predominantly in the form of ALT/AST elevations, gastrointestinal complications, hyperglycemia, reproductive effects. When administered in combination with chemotherapy, primary prophylaxis with growth factor G-CSF is recommended for all patients. For dose adjustments see Information for professionals. **IA:** Co-administration of ketoconazole increases exposure to MMAE. Co-administration of rifampicin reduces exposure to MMAE. Brentuximab vedotin is not expected to alter the exposure to medicines that are metabolized by CYP3A4 enzymes. **P&L:** ADCETRIS should not be used during pregnancy unless it is clearly necessary. The use of during lactation is not recommended. **ADRs:** Very common (≥1/10): infections, peripheral sensory neuropathy, nausea, fatigue, diarrhea, pruritus, upper respiratory tract infections, neutropenia, rash, cough, vomiting, arthralgia, peripheral motor neuropathy, infusion-related

reactions, pruritus, constipation, dyspnea, weight decreased, myalgia, and abdominal pain. Other very common ADRs in combination therapy: alopecia, anemia, stomatitis, febrile neutropenia, decreased appetite, insomnia, bone pain, back pain, dizziness. For further ADRs see Information for professionals. **P:** Vial containing 50 mg brentuximab vedotin: 1, 2 and 10 (10x1 multipack). **Sales category: A. Marketing authorisation holder:** Takeda Pharma AG, 8152 Opfikon, Switzerland. **Detailed information:** www.swissmedicinfo.ch.

References: 1. Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage II/III classical Hodgkin lymphoma: 5-year update of the ECHOLON-1 randomised phase 3 trial. *Lancet Haematol.* 2021. [In press]. 2. Horwitz S, et al. The ECHOLON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-positive Peripheral T-Cell Lymphoma. Presented at ASH 2020; December 5-8, online. Poster 1150. 3. Adcetrís® (brentuximab vedotin) Information for Healthcare Professionals. For further information visit www.swissmedicinfo.ch, accessed April 2021. 4. Pro B, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. *J Clin Oncol.* 2012;30(2):190-2196. 5. Younes A, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. *J Clin Oncol.* 2012;30(18):2183-2189. 6. Moskowitz CH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet.* 2015;385(9980):1853-1562. 7. Prince HM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. *Lancet.* 2017;390(10094):555-566.

All trademarks are the property of their respective owners. ©2021 Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. All rights reserved.

Takeda Pharma AG, Thurgauerstrasse 130, 8152 Opfikon
Tel. 055 451 52 00, Fax 055 451 52 20, www.takeda.ch
© 2021 Takeda Pharma AG



ONCOLOGY

05/2021 C-APROM/INT/ADCE/0048

ACKNOWLEDGEMENTS

We would like to express our sincere gratitude to the Industry Partners who continue to support the Conference. Their unrestricted support is essential to the dissemination of the Scientific and Industry programs to the worldwide community engaged in the study and treatment of lymphoid neoplasms:

AbbVie, Inc.
Acrotech Biopharma
ADC Therapeutics
AstraZeneca
Bayer
BeiGene
Bristol Myers Squibb
Clinigen
CRISPR Therapeutics
Daiichi Sankyo
F. Hoffmann-La Roche
Genmab
Gilead Sciences Europe Ltd.
HTG Molecular Diagnostics
Incyte
Janssen Oncology Pharmaceutical Companies
of Johnson & Johnson
Karyopharm
Kite, a Gilead Company
Loxo Oncology at Lilly
Lymphoma Hub
Miltenyi Biomedicine
MorphoSys
MSD
Novartis Oncology
Pfizer Oncology
Regeneron
Takeda Oncology

We would like to express our sincere gratitude to the following Partners for their precious support, essential to the organization of this Virtual edition of the Conference and to the achievement of its objectives:

American Association for Cancer Research – AACR
City of Lugano
European School of Oncology – ESO
European Society for Medical Oncology Foundation -
ESOF
European Society for Medical Oncology – ESMO
IBSA Foundation for Scientific Research
International Extranodal Lymphoma Study Group - IELSG
International Lymphoma Radiation Oncology Group -
ILROG
Lymphoma Coalition
Saudi Society of Blood & Marrow Transplantation -
SS-BMT
Swiss Cancer League
Swiss Cancer Research Foundation
Union for China Lymphoma Investigators - UCLI
Università della Svizzera Italiana - USI

Join us on **18 June**


16-ICML Virtual Edition Satellite Symposia

Channel 1

Are we going towards a new care paradigm in FL and CLL ?

18 June | 14:00–15:30 CEST

Chair: Stefano Luminari




Channel 1

Advancements of CAR T cell therapies in B-cell malignancies

18 June | 18:00–19:30 CEST

Chair: David Maloney



GENERAL INFORMATION

Swiss Cancer Research Foundation educational grants

Ten educational grants sponsored by the Swiss Cancer Research Foundation have been assigned, on the basis of the abstract evaluation result, to the following young investigators:

Othman Al-Sawaf, Cologne (Germany)	Oral presentation, abstract number 031
Elodie Bal, New York, NY (USA)	Oral presentation, abstract number 004
Doriane Cavalieri, Clermont-Ferrand, France	Oral presentation, abstract number 044
Sanjal H. Desai, Rochester, MN (USA)	Oral presentation, abstract number 066
Julia Driessen, Amsterdam (Netherlands)	Oral presentation, abstract number 021
Leonie Frauenfeld, Tübingen (Germany)	Oral presentation, abstract number 069
Fabian Knörr, Hamburg (Germany)	Oral presentation, abstract number 036
Jordan Krull, Rochester, MN (USA)	Oral presentation, abstract number 041
Kai Rejeski, Munich (Germany)	Oral presentation, abstract number 082
Muchen Zhang, Shanghai, China	Oral presentation, abstract number 026

krebsforschung schweiz
recherche suisse contre le cancer
ricerca svizzera contro il cancro
swiss cancer research

European School of Oncology (ESO)

The 16-ICML Program will be part of the fifth edition of the Certificate of Competence in Lymphoma, a 14-month European Credit Transfer and Accumulation System (ECTS) program developed by the European School of Oncology (ESO) and academically recognized by the University of Ulm. The purpose of the Certificate of Competence is to provide a curriculum of studies to advance knowledge and science in the management of lymphoma patients. Further information can be obtained by visiting www.eso.net



European Society for Medical Oncology (ESMO)

The 16-ICML is an ESMO Educational Partnership meeting.



Climate conscious event

The 16-ICML proudly supports the “International Small Group and Tree Planting (TIST)”, a sustainable project operating in Kenya, Uganda, Tanzania and India.

Discover more about the TIST program → TIST in Uganda





CALQUENCE[®] ▼ (acalabrutinib)

Indications (Switzerland)

CALQUENCE monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) who are 65 years and older or have comorbidities.

CALQUENCE monotherapy is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.

Please refer to the full Prescribing Information for further information.

Adverse events should be reported. Healthcare Professionals are asked to report adverse events via their national reporting system.
Adverse events should also be reported to AstraZeneca by visiting the link below
<https://aereporting.astrazeneca.com/>

Registration conditions can differ from country to country so consult your local label before prescribing. This information was developed based on the Swiss label.

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Saturday, June 19

Channel	Time	Session	Article/ abstract nr.
Channel 1	13:00 – 13:45	“Meet the Professor” session	
		What's new in peripheral T-cell lymphomas	EB 06
		Stefano Luminari, Reggio Emilia (Italy)	
		Live Q&A	
Channel 2	13:00 – 13:45	“Meet the Professor” session	
		Cutaneous T-cell lymphomas – an update 2021	EB 05
		Werner Kempf, Zürich (CH)	
		Live Q&A	
Channel 3	13:00 – 13:45	“Meet the Professor” session	
		Personalised medicine for Hodgkin Lymphoma: mitigating toxicity while preserving cure	EB 04
		Peter W.M. Johnson, Southampton (UK)	
		Live Q&A	
Channel 4	13:00 – 13:45	“Meet the Professor” session	
		Use of available prognostic scores in treatment decision: beyond standard prognostic scores to include molecular/ genetics/imaging	
		John F. Seymour, Melbourne (Australia)	
		Live Q&A	
Channel 1	14:00 – 15:00	Opening of the conference	
		Welcome to attendees	
		Franco Cavalli, Bellinzona (Switzerland)	
		Henry Kaplan Memorial Lecture and ICML Prize	
		Laudatio: Franco Cavalli, Bellinzona (Switzerland)	

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Saturday, June 19

Channel	Time	Session	Article/ abstract nr.
Channel 1	14:00 – 15:00	Towards control of chronic lymphocytic leukemia with targeted agents Michael Hallek, Cologne (Germany)	001
Channel 1	15:15 – 16:45	Plenary session Co-chairs: James Armitage, Omaha, NE (USA) and Franco Cavalli, Bellinzona (Switzerland)	
		Pervasive Hypermutation of Super-enhancer Regions Dysregulates Oncogene Expression in Diffuse Large B-cell Lymphoma Elodie Bal, New York, NY (USA)	004
		Introduced by Ralf Küppers, Essen (Germany)	
		Live Q&A moderated by session chairs	
		Early Positron Emission Tomography Response-Adapted Treatment in Localized Diffuse Large B-Cell Lymphoma (aPI=0): Results of the Phase 3 LYSA LNH 09-1B Trial. Serge Bologna, Essey lès Nancy (France)	005
		Introduced by Jonathan W. Friedberg, Rochester, NY (USA)	
		Live Q&A moderated by session chairs	
		Determinants of resistance to engineered T-cell therapies targeting CD19 in lymphoma Brian Sworder, Stanford, CA (USA)	006
		Introduced by Stephen J. Schuster, Philadelphia, PA (USA)	
		Live Q&A moderated by session chairs	

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Saturday, June 19

Channel	Time	Session	Article/ abstract nr.
Channel 1	17:00 – 18:15	AACR-ICML joint session	
		Artificial intelligence in lymphoma diagnosis and treatment	
		Co-chairs: Riccardo Dalla-Favera, New York, NY (USA), Bertrand Nadel, Marseille (France) and Olivier Elemento, New York, NY (USA)	
		Artificial intelligence and medicine: past and future	007
		Luca M. Gambardella, Lugano (Switzerland)	
		Artificial intelligence and pathology	008
		Pierre Brousset, Toulouse (France)	
		Use of deep learning to analyse and exploit molecular data	009
		Dan A. Landau, New York, NY (USA)	
		How machine learning can enhance clinical development	010
		Paul Trichelair, Paris (France)	
		Live Q&A moderated by session chairs	

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Sunday, June 20

Channel	Time	Session	Article/ abstract nr.
Channel 1	12:00 – 13:30	UCLI-ICML joint session	
		New data on T-cell and other lymphomas	
		Honorary co-chairs: Franco Cavalli, Bellinzona (Switzerland) and Jun Ma, Harbin (China)	
		Executive co-chairs: Stefano Luminari, Reggio Emilia (Italy) and Jun Zhu, Beijing (China)	
		Welcome	
		Jun Zhu, Beijing (China)	
		T-cell lymphoma biopathology: what is new?	
		Laurence de Leval, Lausanne (Switzerland)	
		The epidemiology of malignant lymphoid diseases in China	
		Yu-qin Song, Beijing (China)	
		Recent advances in Extranodal Natural Killer/T-Cell Lymphoma: experiences from the SYSUCC	
		Qing-qing Cai, Guangzhou (China)	
		New treatment options in T-cell lymphoma	
		Stefano Luminari, Reggio Emilia (Italy)	
		The changing faces of EBV+ T/NK-cell lymphomas: diagnostic challenges and advances	
		Xiao-qiu Li, Shanghai (China)	
		Closure	
		Stefano Luminari, Reggio Emilia (Italy)	
Channel 2	12:30 – 13:30	“Innovation in radiotherapy – new dose/fractionation schedules”	
		Workshop organised by the International Lymphoma Radiation Oncology Group (ILROG)	
		Chair: Lena Specht, Copenhagen (Denmark)	

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Sunday, June 20

Channel	Time	Session	Article/ abstract nr.
Channel 2	12:30 – 13:30	Radiation doses in the treatment of lymphomas – what is the evidence? Peter Hoskin, Manchester (UK)	
		Low-dose regimens – new fractionation schemes for indolent lymphomas Joachim Yahalom, New York, NY (USA)	
		Fewer but larger fractions in lymphoma radiotherapy – experience from the COVID emergency fractionation Lena Specht, Copenhagen (Denmark)	
Channel 1	14:00 – 14:45	Gianni Bonadonna Memorial Lecture (in collaboration with American Association for Cancer Research, AACR) Laudatio: Davide Rossi, Bellinzona (Switzerland)	
		The architecture of liquid biopsy research for lymphoma monitoring Ash A. Alizadeh, Stanford, CA (USA)	002
Channel 1	15:00 – 16:30	Educational symposium on High risk follicular lymphoma Chair: Brad Kahl, Saint Louis, MO (USA)	
		Upfront identification of high risk follicular lymphoma Carla Casulo, Rochester, NY (USA)	EB 12
		Vulnerabilities in the tumor and microenvironment in follicular lymphoma Elias Campo, Barcelona (Spain)	EB 11
		High risk follicular lymphoma: treatment options Brad Kahl, Saint Louis, MO (USA)	EB 13
		Live Q&A moderated by session chair	

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Sunday, June 20

Channel	Time	Session	Article/ abstract nr.
Channel 1	16:45 – 17:30	“Meet the Professor” session	
		Molecular diagnostics and reporting in lymphoid malignancies: current status and beyond	EB 09
		Richard Rosenquist Brandell, Stockholm (Sweden)	
		Live Q&A	
Channel 2	16:45 – 17:30	“Meet the Professor” session	
		New drugs and pharmacological interactions in real life	EB 10
		Anastasios Stathis, Bellinzona (CH)	
		Live Q&A	
Channel 3	16:45 – 17:30	“Meet the Professor” session	
		Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approaches	EB 03
		Martin Dreyling, Munich (Germany)	
		Live Q&A	
Channel 4	16:45 – 17:30	“Meet the Professor” session	
		Recognizing but not harming. Borderline B-cell lymphoid proliferations	EB 07
		Leticia Quintanilla-Martinez de Fend, Tübingen (Germany)	
		Live Q&A	
Channel 1	17:45 – 19:15	Session 1: NEW THERAPEUTICS	
		Co-chairs: Francesco Bertoni, Bellinzona (Switzerland) and Gilles Salles, New York, NY (USA)	
		Targeting proximal BCR signaling pathway in diffuse large B-cell lymphoma	011
		Jae Woo Choi, Bethesda, MD (USA)	

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Sunday, June 20

Channel	Time	Session	Article/ abstract nr.
Channel 1	17:45 – 19:15	MALT1 degradation for the treatment of Activated B-Cell type Diffuse Large B-cell Lymphoma Madhav Seshadri, New York, NY (USA)	012
		KT-413, a novel IRAKIMiD Degradator of IRAK4 and IMiD substrates, has a differentiated MOA that leads to single-agent and combination regressions in MYD88MT Lymphoma models Duncan Walker, Watertown, MA (USA)	013
		Live Q&A moderated by session chairs	
		First-in-human study of the EZH1 and EZH2 dual inhibitor valemetostat tosylate (DS-3201b) in patients with relapsed or refractory non-Hodgkin lymphomas Kenj Ishitsuka, Kagoshima, Japan	014
		Glofitamab step-up dosing: updated efficacy data show high complete response rates in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients Carmelo Carlo-Stella, Milan (Italy)	015
		Subcutaneous Epcoritamab in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: Safety Profile and Anti-tumor Activity Martin Hutchings, Copenhagen, Denmark	016
		Live Q&A moderated by session chairs	
Channel 2	17:45 – 19:15	Session 2: LYMPHOMA IMAGING	
		Co-chairs: Sally F. Barrington, London (UK) and Josée Zijlstra-Baalbergen, Amsterdam (Netherlands)	
		Defining ultra-high-risk DLBCL patients prior to initial treatment based on an integrative host and disease prognostic score (from REMARC study) Catherine Thieblemont, Paris (France)	017

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Sunday, June 20

Channel	Time	Session	Article/ abstract nr.
Channel 2	17:45 – 19:15	Integration of baseline metabolic parameters and mutational profile predicts outcome in DLBCL patients. A post hoc analysis of SAKK38/07 study.	018
		Guido Ghilardi, Bellinzona (Switzerland)	
		Baseline Metabolic Tumor Volume and IPS predict ABVD failure in advanced-stage Hodgkin Lymphoma with a negative interim PET scan after two chemotherapy cycles. A retrospective analysis from the GITIL/FIL HD0607 trial	019
		Andrea Gallamini, Nice (France)	
		Live Q&A moderated by session chairs	
		Prognostic role of lesion dissemination feature (Dmax) calculated on baseline PET/CT in Hodgkin Lymphoma	020
		Rexhep Durmo, Modena (Italy)	
Channel 3	17:45 – 19:15	Predictive value of quantitative 18F-FDG-PET-CT radiomics analysis in 174 patients with relapsed/refractory classical Hodgkin lymphoma	021
		Julia Driessen, Amsterdam (Netherlands)	
		Development and validation of a PET radiomics prognostic model for diffuse large B cell lymphoma	022
		Luca Ceriani, Bellinzona (Switzerland)	
		Live Q&A moderated by session chairs	
		Session 3: AGGRESSIVE LYMPHOMAS	
		Co-chairs: Peter M.W. Johnson, Southampton (UK) and Margaret Shipp, Boston, MA (USA)	
Channel 3	17:45 – 19:15	Clonal Hematopoiesis is associated with inferior prognosis in newly diagnosed Diffuse Large B-Cell Lymphoma patients	023
		Jan L. Boegeholz, Stanford, CA (USA)	

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Sunday, June 20

Channel	Time	Session	Article/ abstract nr.
Channel 3	17:45 – 19:15	Whole genome sequencing of matched primary and relapsed DLBCL reveals distinct evolutionary dynamics associated with relapse timing	024
		Laura K. Hilton, Vancouver, B.C. (Canada)	
		Phased variants improve DLBCL minimal residual disease detection at the end of therapy	025
		David Kurtz, Stanford, CA (USA)	
		Live Q&A moderated by session chairs	
		Genetic Subtype Guided Rituximab-based Immunochemotherapy Improves Outcome in Newly Diagnosed Diffuse Large B-cell Lymphoma: First Report of a Randomized Phase 2 Study	026
		Muchen Zhang, Shanghai, China	
Channel 4	17:45 – 19:15	Biomarker-driven treatment strategy in high risk diffuse large B-cell lymphoma: Results of a Nordic phase 2 study	027
		Sirpa Leppä, Helsinki, Finland	
		Long-term analyses from L-MIND, a Phase II study of tafasitamab plus lenalidomide (LEN) in patients (pts) with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)	028
		Johannes Duell, Würzburg, Germany	
		Live Q&A moderated by session chairs	
Channel 4	17:45 – 19:15	Session 4: CHRONIC LYMPHOCYTIC LEUKEMIA	
		Co-chairs: Susan O'Brien, Orange, CA (USA) and Kostas Stamatopoulos, Thessaloniki (Greece)	
		Adaptation of chronic lymphocytic leukemia to ibrutinib is mediated by epigenetic plasticity of residual disease and by-pass signaling via MAPK pathway	029
		Lodovico Terzi di Bergamo, Bellinzona (Switzerland)	

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Sunday, June 20

Channel	Time	Session	Article/ abstract nr.
Channel 4	17:45 – 19:15	Genetic markers and outcome with front line obinutuzumab plus either chlorambucil or venetoclax - updated analysis of the CLL14 trial	030
		Eugen Tausch, Ulm (Germany)	
		Venetoclax-obinutuzumab modulates clonal growth: Results of a population-based minimal residual disease model from the randomized CLL14 study	031
		Othman Al-Sawaf, Cologne (Germany)	
		Live Q&A moderated by session chairs	
		CAPTIVATE primary analysis of first-line treatment with fixed-duration ibrutinib plus venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)	032
		Constantine Tam, Melbourne (Australia)	
		First Results of a Head-to-Head Trial of Acalabrutinib versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia	033
Peter Hillmen, Leeds (UK)			
Channel 4	17:45 – 19:15	Bendamustine, followed by Obinutuzumab, Acalabrutinib and Venetoclax in patients (pts) with relapsed/refractory chronic lymphocytic leukemia (CLL): CLL2-BAAG trial of the GCLLSG	034
		Paula Cramer, Cologne (Germany)	
		Live Q&A moderated by session chairs	

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Monday, June 21

Channel	Time	Session	Article/ abstract nr.
Channel 1	12:30 – 13:30	“The evolving role of Radiotherapy in the salvage treatment for lymphoma in the era of CAR-T therapy”	
		Workshop organised by the International Lymphoma Radiation Oncology Group (ILROG)	
		Chair: Bouthaina S. Dabaja, Houston, TX (USA)	
		Radiation prior to immune-cellular therapy: the science behind the sublethal immunogenic cell death	
		Bouthaina S. Dabaja, Houston, TX (USA)	
		Optimal integration of radiation in salvage therapy for relapsed / refractory lymphoma (including CAR-T)	
		Richard Tsang, Toronto, ON (Canada)	
		Ongoing clinical trials combining radiation and CAR-T	
		George Mikhaeel, London (UK)	
Channel 1	14:00 – 14:45	John Ultmann Memorial Lecture	
		(in collaboration with European School of Oncology, ESO)	
		Laudatio: Emanuele Zucca, Bellinzona (Switzerland)	
		Immune Suppression and Dysfunction in the Tumor Microenvironment in Lymphoma	003
		Stephen M. Ansell, Rochester, MN (USA)	
Channel 1	15:00 – 16:30	Educational symposium on Immunotherapy	
		Chair: Gilles Salles, New York, NY (USA)	
		Optimizing CAR T cell therapy in lymphoma	EB 15
		Gilles Salles, New York, NY (USA)	
		Allogeneic stem cell transplant in non-Hodgkin lymphomas: still an indication?	EB 14
		Peter Dreger, Heidelberg (Germany)	

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Monday, June 21

Channel	Time	Session	Article/ abstract nr.
Channel 1	15:00 – 16:30	Bispecific Antibodies for the Treatment of Lymphomas: Promises and Challenges Stephen J. Schuster, Philadelphia, PA (USA) Live Q&A moderated by session chair	EB 16
Channel 1	16:45 – 17:45	“Challenging cases” session Aggressive NHL Chair: Franco Cavalli, Bellinzona (Switzerland) Case 1: “A patient with abdominal pain” Discussant: Ranjana H. Advani, Stanford, CA (USA) Case 2: “Can we offer a curative treatment to patients with relapsed DLBCL who are not a candidate for autologous stem cell transplant?” Discussant: Urban Novak, Bern (Switzerland) Case 3: “How should I treat patients with MCL relapsing in CNS?” Discussant: Martin Dreyling, Munich (Germany) Case 4: “A 31 year old man with dysphagia” Discussant: Pier Luigi Zinzani, Bologna (Italy)	
Channel 2	16:45 – 17:45	“Challenging cases” session Indolent NHL and CLL Chair: Davide Rossi, Bellinzona (Switzerland) Case 1: “A young patient with leg swelling” Discussant: Ranjana H. Advani, Stanford, CA (USA) Case 2: “The gentleman with acid peptic disease” Discussant: Mary Gospodarowicz, Toronto, ON (Canada) Case 3: “A woman with high-risk CLL and tachycardia” Discussant: Barbara Eichhorst, Cologne (Germany) Case 4: “A young man with triple refractory CLL” Discussant: Barbara Eichhorst, Cologne (Germany)	

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Monday, June 21

Channel	Time	Session	Article/ abstract nr.
Channel 3	16:45 – 17:45	“Challenging cases” session Hodgkin Lymphoma Chair: Alden Moccia, Bellinzona (Switzerland) Case 1: “A sportsman with shortness of breath” Discussant: John Kuruvilla, Toronto, ON (Canada) Case 2: “A late relapse Hodgkin lymphoma” Discussant: Peter W.M. Johnson, Southampton (UK) Case 3: “A 73 year-old woman in the ER” Discussant: James O. Armitage, Omaha, NE (USA) Case 4: “A sportsman with enlarged lymph nodes” Discussants: Peter Borchmann, Cologne (Germany) and Steven Le Guill, Nantes (France)	
Channel 4	16:45 – 17:45	“Challenging cases” session Difficult pathology cases Chair: Luca Mazzucchelli, Locarno (Switzerland) Discussants: Stefan Dirnhofer, Basel (Switzerland) and Alexandar Tzankov, Basel (Switzerland)	
Channel 1	18:00 – 18:45	“Meet the Professor” session Sequencing of myeloma therapy: finding the right path among many standards S. Vincent Rajkumar, Rochester, MN (USA) Live Q&A	EB 08
Channel 2	18:00 – 18:45	“Meet the Professor” session Langerhans Cell Histiocytosis: Version 2021 Carl E. Allen, Houston, TX (USA) Live Q&A	EB 01

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Monday, June 21

Channel	Time	Session	Article/ abstract nr.
Channel 3	18:00 – 18:45	“Meet the Professor” session	
		Molecular classification of aggressive lymphomas – past, present, future	
		Björn Chapuy, Göttingen (Germany)	EB 02
		Live Q&A	
Channel 4	18:00 – 18:45	IBSA Foundation Special Forum	
		Welcome	
		Silvia Misiti, Lugano (Switzerland)	
		Introduction	
		Andrea Alimonti, Bellinzona (Switzerland)	
		Vaccines and monoclonals to regain our freedom	
		Rino Rappuoli, Siena (Italy)	
Channel 1	19:00 – 20:00	THE BIG DEBATE: “DLBCL: one disease, one treatment?”	
		organized by the Oncology Institute of Southern Switzerland (IOSI) (supported by an unrestricted educational grant from GILEAD SCIENCES)	
		Chair: Emanuele Zucca, Bellinzona (Switzerland)	
		DEBATE 1: Are we ready to introduce genetic classification in routine diagnostics?	
		YES. Treatment improvement will not be possible otherwise. Björn Chapuy, Göttingen (Germany)	
		NO. This is not yet feasible in everyday community settings. Leticia Quintanilla Martinez – de Fend, Tübingen (Germany)	
		DEBATE 2: Is frontline R-CHOP still the sole standard?	
		YES. R-CHOP21 remains the standard of care. Laurie Sehn, Vancouver B.C. (Canada)	
		NO. We have already moved beyond R-CHOP.	

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Monday, June 21

Channel	Time	Session	Article/ abstract nr.
Channel 1	19:00 – 20:00	Grzegorz S. Nowakowski, Rochester, MN (USA)	
		DEBATE 3: Will targeted treatments soon inform frontline management?	
		YES. Precision medicine will allow patient-tailored treatment.	
		Margaret Shipp, Boston, MA (USA)	
		NO. CART and agnostic immunotherapies will replace chemotherapy.	
		Stephen J. Schuster, Philadelphia, PA (USA)	
Channel 2	19:00 – 20:30	Session 5 : PEDIATRIC LYMPHOMAS	
		Chair: Wilhelm Wössmann, Hamburg (Germany)	
		Current Status and Challenges in Diagnosis of Childhood NHL	035
		Wolfram Klapper, Kiel (Germany)	
		Dose-adjusted EPOCH-rituximab or intensified B-NHL-BFM-type Therapy for Pediatric Primary Mediastinal B-cell Lymphoma	036
		Fabian Knörr, Hamburg (Germany)	
		An Open-label, Phase 1/2 Study of Frontline Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Paediatric Patients with Advanced Stage Hodgkin Lymphoma	037
		Anna Franklin, Aurora, CO (USA)	
		Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYAs) with Stage III or IV Hodgkin Lymphoma: a Subgroup Analysis From the Phase 3 ECHELON-1 Study	038
		Howland Crosswell, Greenville, SC (USA)	
		A UK population-based study of non-Hodgkin Lymphoma in Teenagers and Young Adults (TYA) - Incidence, treatment and outcomes	039
		Robert Carr, London (UK)	
		Live Q&A moderated by session chair	

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Tuesday, June 22

Channel	Time	Session	Article/ abstract nr.
Channel 1	13:00 – 14:30	Session 6: LYMPHOMA BIOLOGY 1	
		Co-chairs: Elias Campo, Barcelona (Spain) and Ari M. Melnick, New York, NY (USA)	
		Molecular Subclusters of Follicular Lymphoma: a report from the UK's Haematological Malignancy Research Network	040
		Reuben Tooze, Leeds (UK)	
		Somatic Alterations in Follicular Lymphoma Associate with unique Tumor-Cell Transcriptional States and Tumor-Immune Microenvironments.	041
		Jordan Krull, Rochester, MN (USA)	
		CREBBP mediated acetylation of KMT2D in normal and transformed GC B cells	042
		Sofija Vlasevska, New York, NY (USA)	
		Live Q&A moderated by session chairs	
		Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma	043
		Francesca Guidetti, Bellinzona (Switzerland)	
Channel 2	13:00 – 14:30	Session 7: AGGRESSIVE EXTRANODAL ENTITIES	
		Co-chairs: Mary K. Gospodarowicz, Toronto, ON (Canada) and Grzegorz S. Nowakowski, Rochester, MN (USA)	

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Tuesday, June 22

Channel	Time	Session	Article/ abstract nr.	
Channel 2	13:00 – 14:30	Noninvasive detection, classification, and risk stratification of primary CNS lymphomas by ctDNA profiling Jurik A. Mutter, Freiburg (Germany)	046	
		MATRIX induction followed by autologous stem cell transplant or whole-brain irradiation in primary CNS lymphoma. 7-year results of the IELSG32 randomized trial. Andrés J.M. Ferreri, Milan (Italy)	047	
		Intensified (intravenous and intrathecal) CNS prophylaxis in primary testicular diffuse large B-cell lymphoma: 5-year results of the IELSG30 trial. Annarita Conconi, Biella (Italy)	048	
		Live Q&A moderated by session chairs		
		Impact of different induction regimens on the outcome of primary mediastinal B cell lymphoma in the prospective IELSG 37 trial Emanuele Zucca, Bellinzona (Switzerland)	049	
		Outcomes after first-line immunochemotherapy for primary mediastinal B cell lymphoma patients: a LYSA study Vincent Camus, Rouen (France)	050	
		Nivolumab plus brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: Extended follow-up from the phase 2 CheckMate 436 study Pier Luigi Zinzani, Bologna (Italy)	051	
		Live Q&A moderated by session chairs		
		Session 8: PERIPHERAL T/NK-CELL LYMPHOMAS		
		Co-chairs: Stefano Luminari, Reggio Emilia (Italy) and Julie M. Vose, Omaha, NE (USA)		

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Tuesday, June 22

Channel	Time	Session	Article/ abstract nr.
Channel 3	13:00 – 14:30	ESA versus MESA with sandwiched radiotherapy in patients with early-stage natural killer/T-cell lymphoma: a multicentre, randomised, phase 3, non-inferiority trial	052
		Hui-Juan Zhong, Shanghai (China)	
		Allogeneic hematopoietic cell transplantation for peripheral T-cell lymphoma: Comparable outcomes of haplo-identical vs. matched donors. A CIBMTR & EBMT Analysis	053
		Peter Dreger, Heidelberg (Germany)	
		Lacutamab in patients (pts) with advanced mycosis fungoides (MF) according to KIR3DL2 expression: early results from the TELLOMAK phase 2 trial	054
		Martine Bagot, Paris (France)	
		Live Q&A moderated by session chairs	
		Multi-center phase II study of romidepsin plus lenalidomide for patients with previously untreated peripheral T-cell lymphoma (PTCL)	055
Jia Ruan, New York, NY (USA)			
Channel 4	13:00 – 14:30	The Combination of Duvelisib and Romidepsin (DR) Is Highly Active Against Relapsed/Refractory Peripheral T-cell Lymphoma with Low Rates of Transaminitis: Final Results	056
		Steven M. Horwitz, New York, NY (USA)	
		Early Safety and Efficacy Data from a Phase I/II Trial of DZD4205, a Selective JAK1 Inhibitor, in Relapsed/Refractory Peripheral T-Cell Lymphoma	057
		Won-Seog Kim, Seoul (South Korea)	
		Live Q&A moderated by session chairs	
Channel 4	13:00 – 14:30	Session 9: MANTLE CELL LYMPHOMA	
		Co-chairs: Martin Dreyling, Munich (Germany) and John P. Leonard, New York, NY (USA)	

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Tuesday, June 22

Channel	Time	Session	Article/ abstract nr.
Channel 4	13:00 – 14:30	A simple epigenetic signature defines two biologic groups of mantle cell lymphoma Marco M. Bühler, Barcelona (Spain)	058
		A completely genetic prognostic model overcomes clinical prognosticators in mantle cell lymphoma: results from the MCL0208 trial from the Fondazione Italiana Linfomi (FIL) Simone Ferrero, Turin (Italy)	059
		Efficacy and safety of ibrutinib in combination with rituximab as frontline treatment for indolent clinical forms of mantle cell lymphoma. Results of the GELTAMO IMCL-2015 study Eva Giné, Barcelona (Spain)	060
		Live Q&A moderated by session chairs	
		The combination of venetoclax, lenalidomide and rituximab in patients with newly diagnosed mantle cell lymphoma induces high response rates and MRD undetectability. Tycel J. Phillips, Ann Arbor, MI (USA)	061
		SAKK 36/13 - Ibrutinib plus bortezomib and ibrutinib maintenance for relapsed and refractory mantle cell lymphoma: final report of a Phase I/II trial of the European MCL network Urban Novak, Bern (Switzerland)	062
		MCL Induction R ² followed by maintenance in patients with relapsed/refractory mantle cell lymphoma: Interim analysis from the Phase 3b MAGNIFY study Jeff P. Sharman, Eugene, OR (USA)	063
		Live Q&A moderated by session chairs	
Channel 1	14:45 – 16:15	Session 10: LYMPHOMA BIOLOGY 2 Co-chairs: Ralf Küppers, Essen (Germany) and Laura Pasqualucci, New York, NY (USA)	

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Tuesday, June 22

Channel	Time	Session	Article/ abstract nr.
Channel 1	14:45 – 16:15	The topology of MYC rearrangements in double-hit lymphoma is constrained by the preceding IGH-BCL2 rearrangement – an LLMP project	064
		Laura K. Hilton, Vancouver, B.C. (Canada)	
		The mutational landscape of double/triple-hit high-grade B-cell lymphoma with BCL2 rearrangement (DH/TH-BCL2) – an LLMP project	065
		Brett J. Collinge, Vancouver, B.C. (Canada)	
		Do Cell-of-Origin, Double Expresser, and Double Hit Status Affect Outcomes in Relapsed/Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL)? A Prospective Observational Study.	066
		Sanjal H. Desai, Rochester, MN (USA)	
		Live Q&A moderated by session chairs	
		Copy number variation analysis identifies distinct genomic features in adult Burkitt lymphoma	067
Kostiantyn Dreval, Burnaby, B.C. (Canada)			
Key genetic and molecular aberrations identified in both adult and EBV-positive Burkitt lymphoma patients	068		
Nicole Thomas, Burnaby, B.C. (Canada)			
Triple positive (CD10+BCL6+MUM1+) diffuse large B-cell lymphomas in adults are a heterogeneous group enriched in large B-cell lymphomas with IRF4 rearrangement	069		
Leonie Frauenfeld, Tübingen (Germany)			
Live Q&A moderated by session chairs			
Channel 2	14:45 – 16:15	Session 11: HODGKIN LYMPHOMA	
		Co-chairs: Ranjana H. Advani, Stanford, CA (USA) and Bruce D. Cheson, Washington, D.C. (USA)	

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Tuesday, June 22

Channel	Time	Session	Article/ abstract nr.
Channel 2	14:45 – 16:15	Circulating tumor DNA is a prognostic biomarker in classic Hodgkin lymphoma	070
		Maria Cristina Piroso, Bellinzona (Switzerland)	
		Relapses in interim PET-negative limited-stage Hodgkin lymphoma patients receiving ABVD with or without radiotherapy – Analysis of EORTC/FIL/LYSA H10 and UK NCRI RAPID trials	071
		Igor Aurer, Zagreb (Croatia)	
		CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL).	072
		Ann S. LaCasce, Boston, MA (USA)	
		Live Q&A moderated by session chairs	
		New prognostic score incorporating MTV predicts treatment failure in advanced Hodgkin Lymphoma	073
		Sally F. Barrington, London (UK)	
Channel 3	14:45 – 16:15	Nivolumab for relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after autologous transplantation: 5-year overall survival from the phase 2 CheckMate 205 study	074
		Stephen M. Ansell, Rochester, MN (USA)	
		Camidanlumab Tesirine Efficacy and Safety in an Open-label, Multicenter, Phase 2 Study of Patients (pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)	075
		Pier Luigi Zinzani, Bologna (Italy)	
		Live Q&A moderated by session chairs	
Session 12: INDOLENT LYMPHOMAS			
		Co-chairs: Astrid Pavlovsky, Buenos Aires (Argentina) and T. Andrew Lister, London (UK)	

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Tuesday, June 22

Channel	Time	Session	Article/ abstract nr.
Channel 3	14:45 – 16:15	Intratumoral T-cells have a Differential Impact on FDG-PET Parameters in Follicular Lymphoma Karthik Nath, Brisbane (Australia)	076
		Direct-acting antivirals as primary treatment for HCV-associated indolent non-Hodgkin Lymphomas: the prospective BArT study of the Fondazione Italiana Linfomi Michele Merli, Varese (Italy)	077
		Primary extranodal follicular lymphoma in a large retrospective survey of the International Extranodal Lymphoma Study Group (IELSG31) Annarita Conconi, Biella (Italy)	078
		Live Q&A moderated by session chairs	
		Phase II trial of rituximab plus chlorambucil followed by a 2-year subcutaneous rituximab maintenance in MALT lymphoma patients (IELSG38) Maria Cristina Piroso, Bellinzona (Switzerland)	079
		Response adapted post induction therapy in follicular lymphoma: updated results of the FOLL12 trial by the Fondazione Italiana Linfomi (FIL). Stefano Luminari, Reggio Emilia (Italy)	080
		Immune Priming with Nivolumab followed by Nivolumab & Rituximab in 1st Line Treatment of Follicular Lymphoma: The Phase 2 1st FLOR Study Eliza A. Hawkes, Melbourne (Australia)	081
		Live Q&A moderated by session chairs	
Channel 4	14:45 – 16:15	Session 13: CAR-T CELL THERAPY Co-chairs: Paolo Corradini, Milan (Italy) and Peter Dreger, Heidelberg (Germany)	

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Tuesday, June 22

Channel	Time	Session	Article/ abstract nr.
Channel 4	14:45 – 16:15	CAR-HEMATOTOX: A discriminative model for CAR T-cell related hematotoxicity in relapsed/refractory large B-cell lymphoma	082
		Kai Rejeski, Munich (Germany)	
		Early PET response predicts outcome in large B-cell lymphoma patients treated with CD19 CAR-T	083
		Maria Cuadrado, London (UK)	
		First results of DLBCL patients treated with CAR-T cells and enrolled in DESCAR-T registry, a French real-life database for CAR-T cells in hematologic malignancies.	084
		Steven Le Guill, Nantes (France)	
		Live Q&A moderated by session chairs	
		Efficacy and Safety of Tisagenlecleucel (Tisa-cel) in Adult Patients (Pts) With Relapsed/Refractory Follicular Lymphoma (r/rFL): Primary Analysis of the Phase 2 ELARA Trial	085
Nathan H. Fowler, Philadelphia, PA (USA)			
Channel 1	16:30 – 17:00	TRANSCEND CLL 004: Phase 1 cohort of Lisocabtagene Maraleucel (liso-cel) combined with Ibrutinib (ibr) for patients (pts) with R/R CLL/SLL	086
		William G. Wierda, Houston, TX (USA)	
		Outcome of large B-cell lymphoma patients failing CD19 targeted CAR-T therapy	087
		Andrea Kuhn, London (UK)	
		Live Q&A moderated by session chairs	
		Special Lecture: Lymphoma Treatment in Developing Countries	088
		Chair: Franco Cavalli, Bellinzona (Switzerland)	
		Andrea Biondi, Monza (Italy)	

SCIENTIFIC PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Tuesday, June 22

Channel	Time	Session	Article/ abstract nr.
Channel 1	17:00 – 17:30	Take Home Messages	
		James O. Armitage, Omaha, NE (USA)	
		Closure and Farewell	
		Franco Cavalli, Bellinzona (Switzerland)	

POSTER PRESENTATIONS

Poster presentations, abstract numbers from 089 to 287

Lymphoma biology	089 – 106
Indolent lymphomas	107 – 126
Chronic lymphocytic leukemia	127 – 143
Mantle cell lymphoma	144 – 153
Extranodal lymphoma	154 – 165
Aggressive NHL	166 – 188
Hodgkin lymphoma	189 – 207
Pediatric lymphomas	208
Peripheral T/NK Cell lymphomas	209 – 229
New drugs	231 – 245
Ongoing trials	246 – 264
CAR-T cell therapy	265 – 279
Miscellaneous	280 – 287

PEARLS OF *Knowledge*

EXPERT PERSPECTIVES IN THE TREATMENT OF R/R DLBCL

Time is precious: Take 30 minutes out of your ICML agenda to view our innovative series of short video presentations, where clinical experts discuss current treatment options and research into potential new therapies for their patients with R/R DLBCL.



The live 30-minute session will take place at
16:00 (CEST) on 18 June 2021.

Following the congress, all videos will be available
to view **on demand on the ICML conference website.**

Faculty:

Pier Luigi Zinzani, *Italy*

Marco Ladetto, *Italy*

Georg Lenz, *Germany*

Johannes Düll, *Germany*

Martin Dreyling, *Germany*

Guillaume Cartron, *France*

Roch Houot, *France*

Eva Gonzalez Barca, *Spain*

Christopher Fox, *UK*

Armando López-Guillermo, *Spain*

Driving the understanding of DLBCL forward

INDUSTRY PROGRAM

All session times for the 16-IGML are Central European Summer Time (CEST)

Friday, June 18

Channel	Time	Session	Article/ abstract nr.
Channel 1	12:00 – 13:30	Janssen Oncology Pharmaceutical Companies of Johnson & Johnson <hr/> PRECISION MEDICINE IN LYMPHOMA: WHAT DOES IT MEAN? <hr/> Chair: John Gribben, London (UK) <hr/> The power of precision medicine lies in its ability to guide health care decisions toward the most effective treatment strategy for a given patient, and thus, improve the quality of patient care. In this symposium, the expert faculty will evaluate what precision medicine means for the management of patients with B-cell lymphomas. Professor John Gribben will lead a structured roundtable discussion with Professor Steven le Gouill, Professor Steve Treon and Professor Catherine Thieblemont to consider how aspects of precision medicine can be applied in different lymphomas to improve patient care and clinical outcomes. EM-61522	
	12:00 – 12:15	Welcome and introduction <hr/> John Gribben, London (UK)	
	12:15 – 13:00	Structured roundtable discussion: What does precision medicine mean for the management of lymphoma now and in the future? <hr/> Steven Le Gouill, Nantes (France) <hr/> Catherine Thieblemont, Paris (France) <hr/> Steve Treon, Boston (USA) <hr/> All faculty, moderated by John Gribben, London (UK)	
	13:00 – 13:25	Q&A live session <hr/> All faculty, moderated by John Gribben, London (UK)	
	13:25 – 13:30	Closing remarks <hr/> John Gribben, London (UK)	

INDUSTRY PROGRAM

All session times for the 16-IGML are Central European Summer Time (CEST)

Friday, June 18

Channel	Time	Session	Article/ abstract nr.
Channel 2	12:00 – 13:30	AstraZeneca	
		EVOLVING STRATEGIES USING BTK INHIBITORS IN CLL: A SELECTIVE APPROACH TO IMPROVE PATIENT OUTCOMES	
		Chair: Paolo Ghia, Milan (Italy)	
		In this CME-certified, live webinar on 18 June 2021 at 12.00 CEST, Drs. Paolo Ghia, George A. Follows, and Veronique Leblond will discuss the evolving global strategies around using BTK inhibitors in CLL, including the current role of BTKi in CLL, safety concerns, and a discussion of patient cases. Attendees will have the opportunity to have questions answered by these experts, enhancing the interactivity of this webinar.	
		The Current Role of BTK Inhibitors in CLL Paolo Ghia, Milan (Italy)	
A Focus on Safety of BTK inhibitors in the Management of CLL George Follows, Cambridge (UK)			
Practical Case Discussions: Selecting BTK inhibitor Therapy in CLL Véronique Leblond, Paris (France)			
Channel 3	12:00 – 13:15	MSD	
		EXPLORING THE UTILITY OF NOVEL TARGETS IN LYMPHOMAS	
		Chair: Ulrich Jaeger (Austria)	
		Educational Objectives	
		Review the most recent data and the actual treatment landscape in cHL	
		Review the treatment options with BTK inhibitors in CLL and NHL	
	12:00 – 12:10	Welcome and Introduction Ulrich Jaeger (Austria)	

INDUSTRY PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Friday, June 18

Channel	Time	Session	Article/ abstract nr.
Channel 3	12:10 – 12:35	Current treatment landscape in Classical Hodgkin's Lymphoma Jane Winter (USA)	
	12:35 – 13:00	Bruton's Tyrosine Kinase (BTK) inhibition: past, present, future Paolo Ghia (Italy)	
	13:00 – 13:10	Q&A Live Panel Discussion All Faculty	
	13:10 – 13:15	Closing Remarks Ulrich Jaeger (Austria)	
Channel 4	12:00 – 13:30	ADC Therapeutics ELEVATE YOUR KNOWLEDGE ON NOVEL ANTIBODY-BASED THERAPIES TO TREAT R/R DLBCL Chair: Carmelo Carlo-Stella, Milan (Italy)	
		Although first-line chemoimmunotherapy for diffuse large B-cell lymphoma (DLBCL) is highly effective, a substantial proportion of patients develop relapsed or refractory (R/R) disease, which is associated with poor survival outcomes. While current salvage treatments can provide effective disease control in eligible patients with R/R DLBCL, treatment options are limited, and many patients still experience disease progression. Join this year's ADC Therapeutics Satellite Symposium where a panel of experts, chaired by Prof. Carmelo Carlo-Stella, discuss the evolving treatment landscape in R/R DLBCL and the role novel antibody-based therapies might have in meeting this urgent unmet need.	
		12:00 – 12:01	Welcome and Introduction Carmelo Carlo-Stella, Milan (Italy)
	12:01 – 12:20	Aiming to meet the unmet need in R/R DLBCL with novel antibody-based therapies Sonali Smith, Chicago, IL (USA)	

INDUSTRY PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Friday, June 18

Channel	Time	Session	Article/ abstract nr.
Channel 4	12:20 – 12:45	CD19 as a target in DLBCL Weiyun Z. Ai, San Francisco, CA (USA)	
	12:45 – 13:10	Clinical data on CD19-targeted antibody-based therapies in R/R DLBCL Carmelo Carlo-Stella, Milan (Italy)	
	13:10 – 13:30	Live Q&A Discussion and Closing Remarks	
Channel 1	14:00 – 15:30	Bristol Myers Squibb ARE WE GOING TOWARDS A NEW CARE PARADIGM IN FL AND CLL? Chair: Stefano Luminari, Reggio Emilia (Italy) Please join this Bristol Myers Squibb supported Satellite Symposium on the changing treatment landscape of Follicular Lymphoma (FL) and Chronic Lymphocytic Leukemia (CLL) at the 16th ICML Virtual Edition. During the Symposium, Prof. Luminari and Dr. Kittai will address the parameters to define the treatment goals in patients with FL and CLL respectively and discuss the current treatment options including chemotherapy free approaches in FL and CLL. In addition, the question whether chemotherapy-free regimens will replace chemotherapy at least for some subgroups of patients will also be addressed. After the presentations, you are encouraged to join the discussion with the expert speakers during the live Q&A session.	
	14:00 – 14:05	Welcome and Introduction Stefano Luminari, Reggio Emilia (Italy)	
	14:05 – 14:30	Follicular Lymphoma: re-setting the treatment goals and is chemotherapy here to stay in FL? Stefano Luminari, Reggio Emilia (Italy)	

INDUSTRY PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Friday, June 18

Channel	Time	Session	Article/ abstract nr.	
Channel 1	14:30 – 14:55	Chronic Lymphocytic Leukemia: re-setting the treatment goals and is chemotherapy here to stay in CLL? Adam S. Kittai, Columbus, OH (USA)		
		Q&A and discussion All faculty, moderated by Stefano Luminari		
	14:55 – 15:30	Closing remarks Stefano Luminari, Reggio Emilia (Italy)		
Channel 2	14:00 – 15:30	Medscape (supported by an independent educational grant from Takeda) SPOTLIGHT ON LYMPHOMA: ADDRESSING REAL WORLD CLINICAL CHALLENGES FOR HL AND PTCL Chair: Timothy Illidge, Manchester (UK) In this live virtual symposium, three expert faculty will navigate the changing landscape for the treatment of HL and PTCL. The faculty will explore factors to consider when choosing among the available treatment options for both frontline and relapsed/refractory HL, with an emphasis on how to best sequence these treatments. The faculty will also discuss newly available therapies for the frontline treatment of PTCL, including how to manage adverse effects related to their use. Patient cases will be presented to illustrate these concepts, and the faculty panel will discuss evidence-based management of these challenging cases.		
		14:00 – 14:05	Welcome and Introductions Timothy Illidge, Manchester (UK)	
		14:05 – 14:40	Spotlight on the Treatment of HL: Which Regimen, for Which Patient? Martin Hutchings, Copenhagen (Denmark) and Anna Sureda, Barcelona (Spain)	

INDUSTRY PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Friday, June 18

Channel	Time	Session	Article/ abstract nr.
Channel 2	14:40 – 15:10	Spotlight on the Treatment of Newly Diagnosed PTCL: Incorporating New Therapies Into the Treatment Paradigm Timothy Illidge, Manchester (UK)	
	15:10 – 15:30	Shifting focus : What Do You and the Expert Think? Q&A live session Timothy Illidge, Manchester (UK), Martin Hutchings, Copenhagen (Denmark) and Anna Sureda, Barcelona (Spain)	
	15:30	Adjourn	
Channel 3	14:00 – 15:30	AbbVie	
		NOT ALL BISPECIFIC ANTIBODIES ARE CREATED EQUAL Chair: Gilles Salles, New York, NY (USA)	
		We will consider how bispecific antibodies offer a novel approach and treatment paradigm for patients with non-Hodgkin lymphoma (NHL). The science and rationale for bispecific antibodies in NHL will be discussed as we take a look at the mechanistic differences in the bispecific CD3xCD20 class. We will then review the latest preclinical and early phase data, consider where bispecific antibodies fit into the future treatment algorithm, and finish by opening the floor for questions from the audience.	
		Welcome and Introduction Gilles Salles, New York, NY (USA)	
		Bispecific antibodies: a mechanistic review of the pipeline John Gribben, London (UK)	
		Emerging clinical data for bispecific antibodies in NHL Sarit Assouline, Montreal, Quebec (Canada)	
Future perspectives on bispecific antibodies in NHL Gilles Salles, New York, NY (USA)			

INDUSTRY PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Friday, June 18

Channel	Time	Session	Article/ abstract nr.
Channel 3	14:00 – 15:30	Live Q&A session and closing remarks All speakers	
Channel 4	14:00 – 15:30	Pfizer Oncology COVID-19 IN CLL AND B CELL MALIGNANCIES Chair: Toby Eyre, Oxford (UK) Introductory remarks on COVID 19 - Perspective on hematological malignancies patients and clinical research in the era of COVID-19 Toby Eyre, Oxford (UK) Clinical outcomes of CL patients with COVID-19 Lindsey Roeker, New York, NY (USA) Clinical outcomes of B cell lymphoma patients with COVID-19 Toby Eyre, Oxford (UK) Vaccine efficacy in patients with B cell malignancies and impact of anti CD20 antibodies and other targeted therapies on humoral immunity David Knorr, New York, NY (USA)	

INDUSTRY PROGRAM

All session times for the 16-IGML are Central European Summer Time (CEST)

Friday, June 18

Channel	Time	Session	Article/ abstract nr.
Channel 1	16:00 – 17:30	Kite, a Gilead Company	
		BUILDING ON SURVIVAL IN CELL THERAPY: FOCUS ON THE FUTURE	
		Chair: John Gribben, London (UK)	
		CAR T-cell therapy continues to reshape the R/R NHL landscape, with multiple CAR T-cell products now licensed in Europe and the US. Despite successes, questions remain on the future of CAR T-cell therapy. During this interactive symposium, our faculty will discuss how we define survival in lymphoma, examine the impact of CAR T product on survival and share insights into patient management optimisation. Finally, they will explore future directions and advances in cell therapy. We encourage you to take the opportunity to participate in the voting questions and live Q&A, where the faculty will discuss questions submitted by the audience.	
		Welcome and introduction: We have come so far...	
		John Gribben, London (UK)	
		How is CAR T reshaping survival in lymphoma?	
		Armando López-Guillermo, Barcelona (Spain)	
		What is the impact of the CAR T product on achieving survival?	
		Frederick Locke, Tampa, FL (USA)	
		How can we optimise patient management?	
		John Gribben, London (UK) and Marion Subklewe, Munich (Germany)	
		New directions: What does the future hold?	
		Caron Jacobson, Boston, MA (USA)	
		Live audience Q&A	
		All faculty	

INDUSTRY PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Friday, June 18

Channel	Time	Session	Article/ abstract nr.
Channel 2	16:00 – 17:30	Incyte	
		PEARLS OF KNOWLEDGE: EXPERT PERSPECTIVES IN THE TREATMENT OF R/R DLBCL	
		Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are transplant-ineligible tend to have very poor outcomes. There is no standard of care, and the currently available treatments generally result in responses that are not durable. In this symposium, we address key unmet needs for these patients with a series of short videos from DLBCL experts outlining various aspects of how they treat their patients with R/R DLBCL.	
		What is your goal for second-line treatment and further for patients with transplant-ineligible R/R DLBCL?	
		Pier Luigi Zinzani, Bologna (Italy)	
		What is the role of chemo-free regimens for the treatment of R/R DLBCL?	
		Marco Ladetto, Alessandria (Italy)	
		How do you decide which treatment option to use for patients with transplant-ineligible R/R DLBCL? What is the role of new molecules with targets other than CD20?	
		Georg Lenz, Münster (Germany)	
		What are your expectations of median PFS and DoR for patients with non-transplant eligible R/R DLBCL with the current treatment options? What would you consider to be a good response? When would you consider a patient to be cured?	
		Johannes Düll, Würzburg (Germany)	
		Which therapies would you consider (will be considering) for patients with transplant-ineligible R/R DLBCL with CNS involvement?	
		Martin Dreyling, Munich (Germany)	

INDUSTRY PROGRAM

All session times for the 16-IGML are Central European Summer Time (CEST)

Friday, June 18

Channel	Time	Session	Article/ abstract nr.
Channel 2	16:00 – 17:30	What is your approach to the treatment of patients with double- or triple-hit R/R DLBCL?	
		Guillaume Cartron, Montpellier (France)	
		In your experience, are most transplant-ineligible patients also ineligible for CAR T-cell therapy?	
		Roch Houot, Rennes (France)	
		What challenges have you experienced with the early identification of patients eligible for CAR T-cell therapy?	
Eva González Barca, Barcelona (Spain)			
		Which adverse events are of concern to you when treating patients with transplant-ineligible R/R DLBCL?	
		Christopher Fox, Nottingham (UK)	
		In what way does your approach to treatment differ for patients with transplant-ineligible R/R DLBCL who relapse early compared with those who relapse at a later stage?	
		Armando López-Guillermo, Barcelona (Spain)	

INDUSTRY PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Friday, June 18

Channel	Time	Session	Article/ abstract nr.
Channel 3	16:00 – 17:30	Regeneron	
		EVOLVING TREATMENT PARADIGM FOR RELAPSED/ REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA	
		Chair: Pier Luigi Zinzani, Bologna (Italy)	
		The treatment landscape for patients with relapsed/ refractory (R/R) diffuse large B-cell lymphoma (DLBCL) has expanded with therapeutic advances involving novel targets and modalities. New agents under investigation for R/R DLBCL include bispecific antibodies, which are designed to facilitate T-cell activation against tumor cells by binding targets on T cells and tumor cells simultaneously. This symposium will highlight considerations for treating patients with R/R DLBCL using newly available therapies, and discuss the potential impact of emerging bispecific agents on the treatment paradigm in DLBCL. A question-and-answer session will provide the opportunity for participants to engage with faculty experts.	
		Current Landscape and Recent Therapeutic Advances in the Management of R/R DLBCL	
		Pier Luigi Zinzani, Bologna (Italy)	
		Considerations for Evaluating Treatment Options for Patients with R/R DLBCL	
		John Kuruvilla, Toronto (Canada)	
		Understanding Emerging Bispecific Therapies	
		Jeremy Abramson, Boston, MA (USA)	
		Panel Discussion: Exploring the Potential Impact of Bispecific Therapies on the DLBCL Treatment Paradigm	
		Pier Luigi Zinzani, Bologna (Italy)	
		John Kuruvilla, Toronto (Canada)	
		Jeremy Abramson, Boston, MA (USA)	

INDUSTRY PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Friday, June 18

Channel	Time	Session	Article/ abstract nr.
Channel 3	17:15 – 17:30	Live Q&A session John Kuruvilla, Toronto (Canada) and Jeremy Abramson, Boston, MA (USA)	
Channel 4	16:00 – 17:30	Bayer THE EVOLVING TREATMENT LANDSCAPE AND EMERGING NOVEL THERAPIES IN INDOLENT NON-HODGKIN'S LYMPHOMA (iNHL) Chair: Martin Dreyling, Munich (Germany)	
		Despite the recent advances in the treatment of iNHL, many patients with advanced disease experience relapse and resistance to ongoing therapies, underscoring the need to identify novel treatment options and appropriate treatment combinations. In this Bayer-sponsored symposium, our esteemed faculty will explore the evolving treatment landscape and promising therapies for iNHL, including various chemotherapy-free treatment options such as targeted therapies (eg, PI3K inhibitors), CAR-T therapy, and bispecific antibodies. Current and emerging treatment options for relapsed follicular lymphoma (FL) and marginal zone lymphoma (MZL) will be discussed in detail, with a focus on recent key clinical data and ongoing clinical trials. A live Q&A session will provide an opportunity for participants to interact with the faculty experts.	IP01
		Welcome and Opening Remarks Martin Dreyling, Munich (Germany)	
		Current Treatment Landscape and Emerging Therapies in iNHL Gilles Salles, New York, NY (USA)	
		The Evolving Therapeutic Options for Patients With Follicular Lymphoma After First Relapse Pier Luigi Zinzani, Bologna (Italy)	

INDUSTRY PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Friday, June 18

Channel	Time	Session	Article/ abstract nr.
Channel 4	16:00 – 17:30	How to Treat Relapsed Marginal Zone Lymphoma? Challenges and Clinical Considerations Christian Buske, Ulm (Germany)	
		Live Q&A live session All panelists, led by Martin Dreyling, Munich (Germany)	
Channel 1	18:00 – 19:30	Bristol Myers Squibb ADVANCEMENTS OF CAR T CELL THERAPIES IN B-CELL MALIGNANCIES Chair: David Maloney, Seattle WA (USA)	
		Please join this Bristol Myers Squibb supported Satellite Symposium on the Advancements of CAR T cell therapies in B-cell malignancies at the 16th ICML Virtual Edition. During the Symposium, Dr. Maloney and Prof. Mateos will present an overview of the latest data on the use of CAR T cell therapy in DLBCL and Myeloma respectively; how use of CAR T therapy could be optimized and could shape the treatment landscape in B-cell malignancies. Dr. Michael Hudecek will then share his translational insights, with a specific focus on improving patient selection and optimizing outcome. Following the presentations, there will be an opportunity to interact with the faculty at the live Q&A session.	
	18:00 – 18:05	Welcome and Introduction David Maloney, Seattle WA (USA)	
	18:05 – 18:25	Evolution of the CAR T treatment paradigm in DLBCL David Maloney, Seattle WA (USA)	
	18:25 – 18:45	Prime time for CAR T cell therapy in multiple myeloma Maria-Victoria Mateos, Salamanca (Spain)	
	18:45 – 19:05	Understanding scientific advancements with CAR T cell therapy Michael Hudecek, Wurzburg (Germany)	

INDUSTRY PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Friday, June 18

Channel	Time	Session	Article/ abstract nr.
Channel 1	19:05 – 19:30	Q&A and discussion All faculty, moderated by David Maloney, Seattle WA (USA) Closing remarks David Maloney, Seattle WA (USA)	
Channel 2	18:00 – 19:30	F. Hoffmann-La Roche UNLOCKING THE FUTURE: SEARCHING FOR A CURE IN DLBCL Chair: Georg Hess, Mainz (Germany) In this forward-looking symposium, a vision of how novel therapies, and future advances in DLBCL may improve patient care in the next five years will be presented by an expert panel. Interactive discussions, in the form of patient cases and knowledge exchange, will revolve around current treatment pathways and challenges, and how future integrated care solutions may help raise the bar to cure more patients with DLBCL. You will have plenty of opportunities to vote on the cases, and interact with the renowned faculty on the insights and clinical experiences they will share. Where are we now? Georg Hess, Mainz (Germany) Improving outcomes in first-line DLBCL Matthew Matasar, New York, NY (USA) Treatment choices in R/R DLBCL: What, why and when? Christopher Fox, Nottingham (UK) Experts in conversation – Your questions answered All faculty - Live panel discussion and Q&A session Is a cure within reach? A five-year countdown Georg Hess, Mainz (Germany)	

INDUSTRY PROGRAM

All session times for the 16-IGML are Central European Summer Time (CEST)

Friday, June 18

Channel	Time	Session	Article/ abstract nr.
Channel 3	18:00 – 19:30	Lymphoma Hub	
		SEQUENCING OF THERAPIES IN HIGH-RISK RELAPSED/ REFRACTORY LYMPHOMA AND CLL	
		Chair: Gilles Salles, New York, NY (USA)	
		The Lymphoma Hub Satellite Symposium, 'Sequencing of therapies in high-risk relapsed/refractory lymphoma and CLL,' will be presented by an international speaker panel chaired by Gilles Salles. The aim of the virtual symposium is to inform participants of the therapeutic options and the data available to help guide treatment selection for difficult-to-treat relapsed/refractory disease, using case examples of ibrutinib-resistant CLL, early-relapsing FL, TP53-mutated MCL, and primary refractory DLBCL. The presentations will be followed by a live roundtable Q&A discussion with the chair and speakers—Francesc Bosch, Loretta Nastoupil, Steven Le Gouill, and Andrew Davies.	
		Objectives and introductions	
		Gilles Salles, New York, NY (USA)	
		Treatment options for a patient with ibrutinib-resistant CLL	
		Francesc Bosch, Barcelona (Spain)	
		How to treat early relapse in a patient with FL	
		Loretta J. Nastoupil, Houston, TX (USA)	
		Sequencing of therapy for a patient with <i>TP53</i> -mutated MCL	
		Steven Le Gouill, Nantes (France)	
		Sequencing treatment options in primary refractory DLBCL	
		Andrew Davies, Southampton (UK)	
		Roundtable discussion	
		All faculty	

INDUSTRY PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Friday, June 18

Channel	Time	Session	Article/ abstract nr.
Channel 4	18:00 – 19:30	Novartis EXPERT PERSPECTIVES IN CAR-T: IDENTIFICATION, REFERRAL AND MANAGEMENT OF PATIENTS WITH LYMPHOMA Chair: Anna Sureda, Barcelona (Spain) This virtual symposium will discuss the current treatment landscape and unmet needs in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), and future directions to optimize patient outcomes with CAR-T cell therapy. Key discussions will include expert guidance on patient identification, timely use of CAR-T therapy earlier in the third-line setting, overcoming barriers to timely referrals to CAR-T centers, and management of long-term adverse events following CAR-T therapy. A review of the latest CAR-T therapy trial data in R/R FL will also be provided. There will be an opportunity for questions during the Live Q&A. Introductions and opening remarks Anna Sureda, Barcelona (Spain) and Natacha Bolaños, Madrid (Spain) CAR-T cell therapy for DLBCL: optimizing patient outcomes, and future directions Paolo Corradini, Milan (Italy), Anna Sureda, Barcelona (Spain), Luca Arcaini, Pavia (Italy) Expert panel discussion: Management of long-term adverse events following CAR-T cell therapy Anna Sureda, Barcelona (Spain), Pier Luigi Zinzani, Bologna (Italy) and Paolo Corradini, Milan (Italy) CAR-T cell therapy in R/R FL: current landscape and future directions Pier Luigi Zinzani, Bologna (Italy)	

INDUSTRY PROGRAM

All session times for the 16-IGML are Central European Summer Time (CEST)

Friday, June 18

Channel	Time	Session	Article/ abstract nr.
Channel 4	18:00 – 19:30	Live Q&A and closing remarks Anna Sureda, Barcelona (Spain), Paolo Corradini, Milan (Italy), Luca Arcaini, Pavia (Italy), Pier Luigi Zinzani, Bologna (Italy) and Natacha Bolaños, Madrid (Spain)	

INDUSTRY PROGRAM

All session times for the 16-ICML are Central European Summer Time (CEST)

Monday, June 21

Channel	Time	Session	Article/ abstract nr.
Channel 1	19:00 – 20:00	Oncology Institute of Southern Switzerland (IOSI) (supported by an unrestricted educational grant from Gilead Sciences Europe, Ltd, who provided funding) THE BIG DEBATE - DLBCL: ONE DISEASE, ONE TREATMENT? Chair: Emanuele Zucca, Bellinzona, Switzerland DEBATE 1. Are we ready to introduce genetic classification in routine diagnostics? YES. Treatment improvement will not be possible otherwise. Björn Chapuy, Göttingen (Germany) NO. This is not yet feasible in everyday community settings. Leticia Quintanilla-Fend, Tübingen (Germany) DEBATE 2. Is frontline R-CHOP still the sole standard? YES. R-CHOP21 remains the standard of care. Laurie Sehn, Vancouver, B.C., (Canada) NO. We have already moved beyond R-CHOP. Greg Nowakowski, Rochester, NJ (USA) DEBATE 3. Will targeted treatments soon inform frontline management? YES. Precision medicine will allow patient-tailored treatment. Margaret Shipp, Boston, MA (USA) NO. CART and agnostic immunotherapies will replace chemotherapy. Stephen J. Schuster, Philadelphia, PA (USA)	



JOIN US ON
HME-forum.com

Please scan here
to register for the
upcoming webinars



The HME Forum is a resource for clinicians with experience in treating patients with a range of hematologic malignancies.

It combines expert interviews, congress coverage, and roundtable discussions that provide updates on key data to inform clinical practice. Interaction with the faculty is encouraged during the live webinar through real-time Q&A.

Myeloma Connect, Challenges in CLL, and Challenges in NHL are a series of live, interactive broadcasts that individually focus on a specific topic relevant to hematologists treating patients with multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma.



INDUSTRY PROGRAM – VIRTUAL EXHIBITION AREA

The following Companies will be present in the Virtual exhibition area of our platform:

Acrotech Biopharma
ADC Therapeutics
American Association for Cancer Research AACR
AstraZeneca
BeiGene
Bristol Myers Squibb
Clinigen
European School of Oncology Foundation ESOF
F. Hoffmann–La Roche
Genmab
Gilead Sciences Europe Ltd.
HTG Molecular Diagnostics
Incyte
Janssen Oncology Pharmaceutical Companies of Johnson & Johnson
Karyopharm
Loxo Oncology at Lilly
Miltenyi Biomedicine
MorphoSys
Novartis Oncology
Pfizer Oncology
Takeda
VJHemOnc